III-01 Gilbert Koch A multi-response model for rheumatoid arthritis based on delay differential equations in collagen induced arthritic mice treated with an anti-GM-CSF antibody Thursday 09:50-11:05 |
III-02 Julia Korell Modelling red blood cell survival data Thursday 09:50-11:05 |
III-03 Elke Krekels Maturation of glucuronidation; a system specific property Thursday 09:50-11:05 |
III-04 Steve Kuan Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients Thursday 09:50-11:05 |
III-05 Ryuji Kubota A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients Thursday 09:50-11:05 |
III-06 Anna Largajolli Meal Tolerance Test (MTT): Nonlinear Mixed-Effects Modeling of Insulin Secretion Thursday 09:50-11:05 |
III-07 Marc Lavielle Improved diagnostic plots require improved statistical tools. Implementation in MONOLIX 4.0 Thursday 09:50-11:05 |
III-08 Robert Leary Exact Reproducibility of Population PK/PD NLME Numerical Results across Different Computational Environments Thursday 09:50-11:05 |
III-09 Donghwan Lee Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics Thursday 09:50-11:05 |
III-10 Annabelle Lemenuel Diot External evaluation of a Hepatitis C viral kinetic model which links viral dynamics to sustained virologic response (SVR) Thursday 09:50-11:05 |
III-11 Natacha Lenuzza Development of a PK library of parent drug/metabolite integrated models Thursday 09:50-11:05 |
III-13 Lay Ahyoung Lim Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care Thursday 09:50-11:05 |
III-16 Arianna Madrid Aispuro Modelling the sleep effects of Zolpidem in rats using non-homogeneous Markov chain models Thursday 09:50-11:05 |
III-17 Paolo Magni A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies Thursday 09:50-11:05 |
III-18 Eleonora Marostica Population state-space modelling of patient responses in antidepressant studies Thursday 09:50-11:05 |
III-19 Hafedh Marouani Kinetic nomograms assist individualization of drug regimens Thursday 09:50-11:05 |
III-20 Amelie Marsot Population pharmacokinetics of Phenobarbital in neonates and infants. Thursday 09:50-11:05 |
III-21 Maria Matoses Osborne Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia Thursday 09:50-11:05 |
III-22 Hugh McDevitt Technology Roadmap to Support Model Based Drug Development Thursday 09:50-11:05 |
III-23 Christophe Meille PK/PD Model of skin toxicity in animal reported as binary outcome Thursday 09:50-11:05 |
III-24 France Mentré Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics Thursday 09:50-11:05 |
III-25 François Mercier A Bayesian meta-analysis of longitudinal lesion count data in multiple sclerosis patients Thursday 09:50-11:05 |
III-26 Evgeny Metelkin A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration Thursday 09:50-11:05 |
III-27 Enrica Mezzalana Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model Thursday 09:50-11:05 |
III-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients on a calcineurin inhibitor free regimen Thursday 09:50-11:05 |
III-29 Jonas Bech Møller Model-based Analysis of the GLP-1 Response Following an Oral Glucose Tolerance Test (OGTT) Thursday 09:50-11:05 |
III-30 Daniele Morpurgo Predicting the Gemcitabine efficacy by a stochastic language based model Thursday 09:50-11:05 |
III-31 Flora Musuamba-Tshinanu KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD). Thursday 09:50-11:05 |
III-32 Thu Thuy Nguyen Evaluation of Fisher information matrix using Gaussian quadrature in nonlinear mixed effects models: application to dose-response trials Thursday 09:50-11:05 |
III-33 Thu Thuy Nguyen Designing a dose-response study analysed by nonlinear mixed effects models Thursday 09:50-11:05 |
III-34 Ronald Niebecker Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance Thursday 09:50-11:05 |
III-35 Christoph Niederalt Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats Thursday 09:50-11:05 |
III-36 Elisabet Nielsen PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models Thursday 09:50-11:05 |
III-37 Valerie Nock Leukopenia following triple high-dose chemotherapy and stem cell rescue Thursday 09:50-11:05 |
III-38 Joakim Nyberg Parallelization in optimal experimental design using PopED Thursday 09:50-11:05 |
III-39 Joakim Nyberg Population optimal design with correlation using Markov Models Thursday 09:50-11:05 |
III-40 Kayode Ogungbenro A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation Thursday 09:50-11:05 |
III-41 Oliver Ackaert Population modelling of blood pressure: assessing clinically important factors for cardiovascular diseases Thursday 09:50-11:05 |
III-42 Erik Olofsen Population Analysis of Kalman-Filtered Permutation Entropy of the Electroencephalogram Thursday 09:50-11:05 |
III-43 Itziar Oteo Differences among six prevalent creatinine clearance calculation methods by covariate modeling of CL for Netilmicin using NONMEM for inference Thursday 09:50-11:05 |
III-44 Zinnia Parra-Guillen Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy Thursday 09:50-11:05 |
III-45 Parul Patel Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children Thursday 09:50-11:05 |
III-46 Joanna Peng A Mechanistic Model for the Effects of A Novel Drug on Glucose, Glucagon and Insulin Applied to Adaptive Phase II Design Thursday 09:50-11:05 |
III-47 Mark Penney Using Mechanistic Modelling of Cyclic Neutropenia to Predict the Effects of a COPD Therapeutic on Systemic Neutrophil Levels Thursday 09:50-11:05 |
III-48 Henry Pertinez Physiologically based, POP-PK modelling of Strontium Ranelate in the ovariectomised rat disease model of post menopausal osteoporosis. Thursday 09:50-11:05 |
III-49 Kirill Peskov A Quantitative Systems Pharmacology Model Provides Insights into Phosphate Homoeostasis through Multiple Interacting Pathways Thursday 09:50-11:05 |
III-50 Kirill Peskov Systems Modeling of EphB4/ephrinB2 Signaling Pathways Thursday 09:50-11:05 |
III-51 Klas Petersson Assessment of bias in model parameter estimates of continuous time Markov models for categorical data Thursday 09:50-11:05 |
III-52 Olivier Petricoul From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose. Thursday 09:50-11:05 |
III-53 Chiara Piana Impact of non-adherence to antiretroviral therapy in HIV-infected children Thursday 09:50-11:05 |
III-54 Anna Fröhleke Development of a PBPK model of doxorubicin Thursday 09:50-11:05 |
III-56 Venkatesh Pilla Reddy Exposure-Response Relationship of Typical and Atypical Antipsychotics Assessed by the Positive and Negative Syndrome Scale (PANSS) and its Subscales Thursday 09:50-11:05 |
III-57 Gregory Pinault A structured approach to industrialize the data sourcing to support model based drug development Thursday 09:50-11:05 |
III-58 Bart Ploeger Confirmation of symptomatic and disease modifying effects of levodopa using the ELLDOPA study Thursday 09:50-11:05 |
III-59 Italo Poggesi Efficiency criteria generated by optimal design tools should be evaluated in the light of study objectives Thursday 09:50-11:05 |
III-60 Klaas Prins Modeling urge urinary incontinence data acknowledging non-Poisson dispersion of counts within individual provides a major model fit improvement. Thursday 09:50-11:05 |
III-61 Klaas Prins Use of a generalized poisson model to describe micturition frequency in patients with overactive bladder disease. Thursday 09:50-11:05 |
III-63 Dinko Rekic Bilirubin - a biomarker of atazanavir exposure in HIV/AIDS patients Thursday 09:50-11:05 |
III-64 Elba Romero PK/PD sampling design optimization following a sustained release formulation of triptorelin using optimal experimental design Thursday 09:50-11:05 |
III-65 Martijn Ruppert Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor Thursday 09:50-11:05 |